Copy Link Print Information

XAV-939

190 Cited Publications
カスタマーレビュー

Based on 190 publication(s) in Google Scholar

XAV-939 is a Tankyrase inhibitor. XAV-939 has inhibitory activity for TNKS1 and TNKS2 with IC50 values of 5 nM and 2 nM, respectively. XAV-939 also is an enhancer of osteoblastic differentiation of hMSCs. XAV-939 can be used for the research of conditions associated with activated Wnt signaling, such as cancer, fibrotic diseases and conditions associated with low bone formation.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

  • 純度: 99.80%
  • CAS 番号: 284028-89-3
  • 分子式: C14H11F3N2OS
  • 分子量:312.31
  • 保管条件:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 1 year , -20°C, 6 months
  • XAV-939 Chemical Structure
    XAV-939 構造式
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
  • Experimental Validation Results for XAV-939
CAS 番号: 284028-89-3
容量
価格（税別）
在庫状況
数量
Amount: USD 0.00
Please select quantity
or
or

* アイテムを追加する前、数量をご選択ください

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of XAV-939:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
最寄りの代理店をお探しください Your local distributor: Hycultec GmbHHycultec
  • 生物活性
  • 化学情報
  • 溶剤 & 溶解度
  • 純度とドキュメンテーション
  • 参考文献
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

MedChemExpress（MCE）の使用を引用している文献 XAV-939

More
Customer Validation & Images
2D/3D Cell Culture and DifferentiationIFWB
  • WB
  • 2D/3D Cell Culture and Differentiation
  • IF
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB

PARP アイソフォーム固有の製品をすべて表示

More
Keywords
100 mg

お問い合わせ 在庫あり

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress ログイン
Register
Sign in to MedChemExpress
新規会員登録

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • XAV-939 Chemical Structure
    XAV-939 Chemical Structure
    1/16
  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2023 Jun 7;15(6):e17101. [Abstract]

    Customer Validation
     XAV939 (20 μM; 3 days) restores the expression of Homer1, PSD95, and GluR1 in Shank3 knockout (KO) human neurons.

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Nature. 2022 Jan;601(7894):600-605. [Abstract]

    Customer Validation
     Upon exposure to lysophosphatidic acid (LPA) (a Hippo pathway inhibitor), A83-01 (an inhibitor of TGFβ family receptors) and PD0325901 (an ERK inhibitor) in a chemically defined medium containing the STAT activator leukaemia inhibitory factor (LIF) and Y-27632 (a ROCK inhibitor) (10 µM, 7 days),blastocyst-like structures formed efficiently from naive PSCs.

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Nature. 2022 Jan;601(7894):600-605. [Abstract]

    Customer Validation
     Upon exposure to lysophosphatidic acid (LPA) (a Hippo pathway inhibitor), A83-01 (an inhibitor of TGFβ family receptors) and PD0325901 (an ERK inhibitor) in a chemically defined medium containing the STAT activator leukaemia inhibitory factor (LIF) and Y-27632 (a ROCK inhibitor) (10 µM, 7 days), blastocyst-like structures formed efficiently from naive PSCs. trophectoderm (TE) cell analogues (identified as GATA2+GATA3+CDX2+TROP2+) formed, proliferated, and established adherens junctions (marked by CDH1), apical-basal polarity (indicated by aPKC) and tight junctions (marked by ZO-1).

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Ecotoxicol Environ Saf. 2023 Jan 1:249:114410. [Abstract]

    Customer Validation
     XAV-939 (5 μM) significantly decreases the expression level of β-catenin in A549 cells.

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Am J Physiol Renal Physiol. 2020 Sep 1;319(3):F458-F468. [Abstract]

    Customer Validation
     Representative Western blot showing FN protein abundance in HMCs cultured in media containing NG or HG in the absence or presence of liraglutide (100 nM) or DMSO (1:1000) or XAV-939 (5 μM) for 24 h.

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Jan 18;9(2):27. [Abstract]

    Customer Validation
     The cellular locations of β-catenin are detected by western blot. GAPDH, Histone H3, and ATP1A1 are used to normalize protein expression in total lysates and nuclear and membrane fractions, respectively. SGC-7901 cells with PCDHGA9 overexpression or vector control cells are grown in media with or without 10 μg/mL inhibitor of β-catenin (XAV-939).

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2018 Jun 21:9:660. [Abstract]

    Customer Validation
     By Western blotting, the α-SMA and palladin proteins are determined in cells that are pretreated with NF-κB (JSH-23), Wnt/β-catenin (XAV939), EGFR (CP-358774), p38 MAPK (TAK-715), and Smad3 (SIS3) inhibitors and are followed by TWEAK stimulation.

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Anticancer Drugs. 2018 Mar;29(3):208-215. [Abstract]

    Customer Validation
     SUM159 sphereforming cells are treated with 15 μM XAV-939 for 7 days, and the protein expression levels of breast cancer stem cells (CSCs) markers are detected by western blotting.

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Anticancer Drugs. 2018 Mar;29(3):208-215. [Abstract]

    Customer Validation
     SUM159 sphere-forming cells are treated with GDC-0449 (15 μM), a Smoothened (Smo) inhibitor for 7 days, and the protein expression levels of breast cancer stem cells (CSCs) play markers are detected by western blotting.

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2018 Sep 10;503(3):2061-2067. [Abstract]

    Customer Validation
     Western blot analysis and alizarin red staining of hDFSCs transfected by EZH2-siRNA and treated by XAV-939. DMSO is used as a vehicle control.

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Biomed Res Int. 2017:2017:1972608. [Abstract]

    Customer Validation
     To investigate the roles of β-catenin, XAV939 (β-catenin inhibitor) was added to MNT group. Total protein is used to observe the expression of Nrf2 and LC3.

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):E1898-906. [Abstract]

    Customer Validation
     Analysis of the in vitro role of the Wnt/β–catenin pathway in the regulation of AQP2 expression in response to sPRR-His treatment. Effect of XAV on sPRR-His-induced AQP2 expression (n = 6 per group).

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2016;39(1):360-70. [Abstract]

    Customer Validation
     EGF upregulates the expression of follicle-regulatory genes via Wnt/β-catenin signaling pathway. (A) The mRNA and (B, C) the protein levels of Survivin, Msx2 and SGK3 in the ORS cells with EGF treatment/overexpression and/or XAV-939 treatment.

  • 1/16

    XAV-939 purchased from MedChemExpress. Usage Cited in: Comp Biochem Phys B. 2016 Jan;191:155-62. [Abstract]

    Customer Validation
     The protein expression of Wnt10b and p-GSK-3β is significantly induced by LiCl treatment (A and B). Nevertheless, XAV939 treatment significantly inhibits the protein expression of p-GSK-3β (B). Moreover, the protein expression of p-β-catenin is significantly inhibited by LiCl treatment, but significantly induced by XAV939 treatment (C).

  • XAV-939